Abbott (NYSE: ABT), a United States-based medical devices and health care company, has launched its NeuroSphere myPath, a digital health app, it was reported on Thursday.

The app aims to track and report patient perceived pain relief and general well-being associated with spinal cord stimulation or dorsal root ganglion therapy. During the device trial period required before the permanent implant, it enables patients to record their outcomes on pain and well-being while trialling their neurostimulation therapy.

The app can connect with Abbott support, access educational resources and track the progress of the patient's trial pain relief journey through their Apple mobile device. The NeuroSphere myPath will be available on the Apple App Store in the coming weeks and is expected to be available on Android devices in Q2 2021.